Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Developmental issues in deaf children

L S Schilling, E DeJesus

    Journal of Pediatric Health Care : Official Publication of National Association of Pediatric Nurse Associates & Practitioners
    |July 1, 1993
    PubMed
    Summary

    Deaf children

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials.

    HIV medicine·2018
    Same author

    The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir.

    HIV medicine·2015
    Same author

    A single amino acid substitution in the group 1 Trypanosoma brucei gambiense haptoglobin-hemoglobin receptor abolishes TLF-1 binding.

    PLoS pathogens·2013
    Same author

    SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2013
    Same author

    Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.

    HIV medicine·2012
    Same author

    96-week results of a pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: the SHIELD trial.

    HIV clinical trials·2011

    Area of Science:

    • Developmental Psychology
    • Pediatrics
    • Linguistics

    Background:

    • Language acquisition is a central challenge for deaf children.
    • Developmental delays are not inevitable for deaf children.
    • Most deaf children have hearing parents, yet research often overlooks their unique developmental needs.

    Purpose of the Study:

    • To provide an overview of deaf child development.
    • To highlight factors influencing language acquisition in deaf children.
    • To discuss implications for caregiving and environmental support.

    Main Methods:

    • Literature review and synthesis of existing research on deaf child development.
    • Comparative analysis of developmental outcomes for deaf children with deaf versus hearing parents.
    • Discussion of caregiving strategies and environmental influences.

    Main Results:

    • Deaf children with deaf parents show fewer developmental issues than those with hearing parents.
    • Early language acquisition is crucial for overall development in deaf children.
    • Significant knowledge gaps exist regarding optimal environmental support for deaf children.

    Conclusions:

    • Early language intervention is critical for deaf children's development.
    • Understanding the role of parental hearing status is key to supporting deaf children.
    • Further research is needed to identify effective caregiving and environmental strategies.

    Related Experiment Videos